http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113952451-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35ec2969250135513ba169bf9098fafc |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2021-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11b16adf721ddf519a1e0c513943ff52 |
| publicationDate | 2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113952451-A |
| titleOfInvention | Combined medicine composition for treating cancer and application thereof |
| abstract | The invention relates to the field of biological medicines, and particularly provides a combined medicine composition for treating cancers, which comprises a tinib medicine and a VEGFR-2 resisting monoclonal antibody taking VEGFR-2 as a target spot. The tinib drugs and the VEGFR-2-resistant monoclonal antibody drugs are combined for application, so that the drug safety is high, the treatment response duration is effectively prolonged, the progression-free survival period and the total survival period of a cancer patient are prolonged, the health condition and the survival quality of the patient are improved, the combined drug composition can be used for treating various cancers such as non-small cell lung cancer, glioma, colorectal cancer, liver cancer, HER2 negative metastatic breast cancer, metastatic gastric adenocarcinoma, metastatic melanoma, metastatic renal cell carcinoma and the like, and particularly can be effectively used for treating the non-small cell lung cancer. |
| priorityDate | 2021-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 243.